KEDI U.S. Medical AI Index
The index consists of U.S.-listed equities that are highly related to medical AI.
Sentiment Summary
Recent Events
Next quarterly earnings report scheduled.
NVIDIA Q1 FY2027 earnings release and conference call scheduled. Low importance is estimated as a date announcement typically has >=1% price impact.
First quarter 2026 earnings release and conference call, for which low impact is estimated as the event has not yet occurred, scheduled.
Tempus AI is expected to release its Q1 2026 earnings on May 5, 2026. Analysts forecast an EPS of -$0.21 to -$0.30, with the market pricing in a potential post-earnings stock price move of over 15% scheduled.
Q1 2026 financial results and corporate update scheduled.
Q1 2026 earnings release for May 4, 2026, with analysts forecasting EPS of approximately -$0.27 and revenue of $20.73 million; Medium importance reflects expected volatility, and the event is scheduled.
First quarterly earnings report for Q1 2026 on May 3, 2026, with analysts forecasting an EPS loss of $0.44 to $0.48. High importance is estimated as the first earnings release often causes significant volatility, scheduled.
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, followed by a conference call. High impact is estimated due to significant market focus on GLP-1 sales growth scheduled.
Alphabet to announce its first quarter 2026 financial results after market close on April 29, 2026. High importance is assigned as earnings reports typically trigger significant price volatility, expected.
AbbVie first quarter 2026 earnings release is scheduled for April 29, 2026.
AstraZeneca's Q1 2026 results announcement is scheduled for April 29, 2026 scheduled
Intuitive Surgical's Q1 2026 earnings release is set for April 21, 2026, after market close, with analysts forecasting EPS of $2.08 and revenue of $2.62 billion; a Medium impact is estimated as earnings typically drive significant price movement scheduled.
Stock rose over 13% following news that the FDA will hold an advisory committee meeting in July 2026 to review potentially easing restrictions on certain compounded peptide products.
Eli Lilly is expected to announce Foundayo's heart safety trial results and the FDA's request for additional data on April 16, 2026. Medium impact is estimated based on the clinical significance of obesity treatments expected.
On April 15, 2026, Tempus announced a collaboration with Predicta Biosciences to launch GenoPredicta, a whole-genome sequencing assay for hematologic cancers and measurable residual disease (MRD) monitoring.
On April 14, 2026, the company launched NVIDIA Ising, a family of open-source AI models designed to accelerate research in quantum computing. Low importance is estimated as this niche product launch is expected to have a >=1% price impact.
The FDA approved the first generic versions of AstraZeneca's blockbuster Type 2 diabetes drug, Farxiga, on April 13, 2026. This will introduce significant competition and likely lead to sales erosion.
On April 13, 2026, AbbVie entered into an exclusive license agreement with Haisco Pharmaceutical to develop and commercialize a portfolio of novel pain compounds.
On April 13, 2026, Tempus launched an automated 'Active Follow-Up' service to provide updated therapy guidance for oncology providers as clinical guidelines change, without requiring new patient samples.